RCS - Ondine Biomedical - Steriwave Featured on CNBC’s Worldwide Exchange

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250910:nRSJ7557Ya&default-theme=true

RNS Number : 7557Y  Ondine Biomedical Inc.  10 September 2025

10 September 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Steriwave Featured on CNBC's Worldwide Exchange

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering
light-activated, non-antibiotic infection prevention therapies, announces that
its Steriwave(®) nasal photodisinfection technology received international
media attention when it was highlighted yesterday on CNBC's Worldwide
Exchange by former President of Mexico, Vicente Fox.

During the interview, Mr. Fox emphasized the global need to address antibiotic
resistance (AMR), particularly in combatting hospital-acquired infections and
protecting healthcare workers. He underscored the urgent need for innovative,
effective infection-prevention strategies like Steriwave, a cost effective,
non-antibiotic therapy that does not generate resistance. He indicated that
there is a critical role for light-activated antimicrobial technologies in
combating the escalating global threat of multidrug-resistant infections,
especially in developing nations where, for most people, access to medicine
and healthcare is limited.

Dr. Nicolas Loebel, President and CTO of Ondine Biomedical, stated:

"We are pleased that Steriwave photodisinfection and the urgent issue of
antimicrobial resistance were both spotlighted on CNBC's Worldwide Exchange.
This recognition underscores our leadership advancing non-antibiotic
infection-prevention solutions and our global mission to deliver simple
solutions to combat complex multidrug-resistant infections."

As previously announced on August 11, 2025, President Fox is serving as Chair
of the Light Against AMR Initiative, a strategic program co-sponsored by
Ondine Biomedical and the International Photodynamic Association. The Light
Against AMR Initiative is dedicated to accelerating the deployment of
affordable, light-based infection control technologies in fast-growing,
underserved, and emerging markets worldwide.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

Correction note: During the broadcast, Mr. Fox was introduced and at one point
referred to himself as a member of Ondine's Board of Directors. This was in
error. Mr. Fox is not a member of Ondine's Board.

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFFEAVIILIE